Phase 2 N=20 Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate
Dysentery · Shigella · Diarrhea
Primary: Number of Participants With Adverse Events — 9; 5; 8; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas
Basal Cell Carcinoma (BCC) · Skin Cancer
Primary: Ki67 Tumor Proliferation Biomarker — 18; 0; -19; 13 Mean percent change — p=0.04
Phase 2 N=34 Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI
Leukemia
Primary: Progression-free Survival — 2; 0 Participants
Phase 2 N=60 Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion
Pulmonary Tuberculosis
Primary: Number of Adverse Events — 5; 4; 10; 8 participants
Phase 2 N=15 Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
Chronic Granulomatous Disease
Primary: Percentage of Participants With Engraftment — 100 percentage of participants
Phase 2 N=356 Comparison of Loss of Resistance Techniques
Pain Relief
Primary: Success of Spinal Labor Analgesia From Combined Spinal Epidural — 163; 161 Participants — p=>.05
Phase 2 N=410 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs, Withdrawals Due to AEs — 358; 148; 91; 90 Participants
Phase 2 N=192 Dose-ranging Efficacy of Polydextrose Supplement on Colonic Transit Time and Symptoms in Adults With Functional Constipation
Functional Constipation
Primary: Change in Colonic Transit Time From Baseline to Day 15 — -1.7; 4.0; 2.5; 2.6 Hours
Phase 2 N=110 Safety Evaluation of 3K3A-APC in Ischemic Stroke
Ischemic Stroke
Primary: Number of Participants With Adverse Events That Meet Dose-limiting Toxicity (DLT) Criteria Specified in Protocol — 0; 1; 0; 0 Participants
Phase 2 N=47 Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel
Acute Pain · Breast Carcinoma · Peripheral Neuropathy
Primary: Area Under the Curve (AUC) Per Assessment (aAUCpa) of Average Pain (Item 3 on the Daily Post-Paclitaxel Questionnaire) — 96.0; 84.3 scores on a scale — p=0.0186
Phase 2 N=413 University of Wisconsin Meditation & Exercise Cold Study
Acute Respiratory Infection
Primary: Severity-weighted Total Days of ARI Illness — 1045; 1010; 1210 severity*days
Phase 2 N=25 Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Recurrent Melanoma · Stage IV Melanoma
Primary: Progression-Free Survival at 4 Months — 22.2 percentage of patients
Phase 2 N=107 An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects
Psoriasis Vulgaris
Primary: Adverse Drug Reactions (ADRs) — 2; 1; 1; 1 Number of adverse drug reactions
Phase 2 N=66 A Study of Enzastaurin in Participants With Follicular Lymphoma
Lymphoma, Follicular
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 26.4 percentage…
Phase 2 N=10 Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
Rett Syndrome
Primary: Gait Velocity as Measured by GAITRite System — 62.7; 84.3 cm/sec — p=0.03